PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of diabetesSubscribeSearchDiabetes JournalAmerican Diabetes Association
 
Diabetes. 2009 April; 58(4): 813–819.
Published online 2009 January 9. doi:  10.2337/db08-1515
PMCID: PMC2661576

Relationship of Metabolic Syndrome With Incident Aortic Valve Calcium and Aortic Valve Calcium Progression

The Multi-Ethnic Study of Atherosclerosis (MESA)*

Abstract

OBJECTIVE

Metabolic syndrome (MetS) has been associated with increased prevalence of aortic valve calcium (AVC) and with increased progression of aortic stenosis. The purpose of this study was to determine whether MetS is associated with increased risks for the development of new (“incident”) AVC or for progression of established AVC as assessed by CT.

RESEARCH DESIGN AND METHODS

The relationships of MetS or its components as well as of diabetes to risks for incident AVC or AVC progression were studied among participants with CT scans performed at baseline and at either year 2 or year 3 examinations in the Multi-Ethnic Study of Atherosclerosis (MESA).

RESULTS

Of 5,723 MESA participants meeting criteria for inclusion, 1,674 had MetS by Adult Treatment Panel III criteria, whereas 761 had diabetes. Among the 5,123 participants without baseline AVC, risks for incident AVC, adjusted for time between scans, age, sex, race/ethnicity, LDL cholesterol, lipid-lowering medications, and smoking, were increased significantly for MetS (odds ratio [OR] 1.67 [95% CI 1.21–2.31]) or diabetes (2.06 [1.39–3.06]). In addition, there was an increase in incident AVC risk with increasing number of MetS components. Similar results were found using the International Diabetes Federation MetS criteria. Among the 600 participants (10.5%) with baseline AVC, neither MetS nor diabetes was associated with AVC progression.

CONCLUSIONS

In the MESA cohort, MetS was associated with a significant increase in incident (“new”) AVC, raising the possibility that MetS may be a potential therapeutic target to prevent AVC development.

Metabolic syndrome (MetS) is a collection of clinical and laboratory abnormalities comprised of central adiposity, hypertriglyceridemia, low HDL cholesterol, elevated blood pressure, and/or impaired fasting glucose (1,2). Overall MetS prevalence has been estimated at ~25% in Western populations (2,3) but is almost certainly increasing as a consequence of the worldwide epidemic of obesity (4,5). MetS is associated with both increased prevalence of coronary atherosclerosis (1,2,6,7) and increased risk for clinical cardiovascular events (8,9).

Cross-sectional U.S. data show that the prevalence of MetS increases with age (3), suggesting that MetS might contribute to risk for diseases with increased prevalence in the elderly. Examples of these diseases include both atherosclerosis (10) and calcific aortic valve disease (CAVD), which has a prevalence of 25% in those older than age 65 years (11). CAVD is comprised of aortic sclerosis, in which the valve is calcified and thickened but does not obstruct left ventricular outflow, and aortic stenosis, in which obstruction to left ventricular outflow is present (12,13). Aortic sclerosis is associated with an ~50% increase in cardiovascular events (14), and aortic stenosis is associated with a 5-year risk of 80% risk for valve replacement surgery or clinical cardiovascular events (15).

Previous studies have shown that the MetS and diabetes are associated with the presence of coronary artery calcium as assessed by cardiac CT (7). In the Multi-Ethnic Study of Atherosclerosis (MESA) cohort, in which the overall MetS prevalence by Adult Treatment Panel (ATP) III criteria is 21%, not only is MetS associated with increased prevalence of CT-detected aortic valve calcium (AVC), but also increased number of MetS features is associated with increased AVC prevalence (16). Metabolic syndrome also has been associated with increased progression of aortic stenosis (17) and accelerated degeneration of bioprosthetic aortic valves (18).

It is not known, however, whether abnormalities in glucose metabolism/insulin resistance, as typified by the clinical syndromes of MetS and diabetes, are associated with increased likelihood of incident (“new”) AVC or AVC progression. We sought to evaluate potential associations of the MetS and diabetes both in the development of incident AVC as well as in the progression of established AVC using data from a multi-ethnic cohort of men and women, MESA.

RESEARCH DESIGN AND METHODS

Study population.

The MESA cohort consists of 6,814 men and women, aged 45 to 84 years, recruited from six U.S. communities (Baltimore, MD; Chicago, IL; Forsyth County, NC; Los Angeles County, CA; northern Manhattan, NY; and St. Paul, MN) and who were free of clinically evident cardiovascular disease at the time of enrollment (baseline). The main objective of MESA is to determine the characteristics of subclinical cardiovascular disease and its progression. Participants were excluded if they had a history of any of the following procedures: coronary bypass surgery, balloon angioplasty, heart valve replacement, pacemaker or defibrillator implantation, or history of any other cardiac surgery. The study was designed to include the following self-identified ethnic groups: whites, African Americans, Hispanics, and Chinese Americans. Sampling and recruitment procedures have been previously described in detail (19). Participants were enrolled between 1 August 2000, and 30 July 2002. The institutional review boards at all participating centers approved the study, and all participants gave informed consent.

Questionnaires were used to obtain information about socioeconomic status, medical history, medication, and tobacco use. Smoking was defined as current, former, or never. Waist circumference at the umbilicus was measured to the nearest 0.1 cm using a steel measuring tape (standard 4-ounce tension). Resting blood pressure was measured three times with participants in the seated position with a Dinamap model Pro 100 automated oscillometric sphygmomanometer (Critikon). The average of the last two measurements was used in this analysis. Total and HDL cholesterol, triglycerides, and glucose levels were measured from blood samples obtained after a 12-h fast. LDL cholesterol was calculated with the Friedewald equation (20).

Diabetes and metabolic syndrome.

Participants were considered to have diabetes if they met the following criteria: self-reported history of adult onset of diabetes, fasting glucose 126 mg/dl or greater, or use of insulin or oral glucose-lowering medications.

Among those without diabetes, MetS was defined using ATP III (21)–modified criteria. These criteria require three or more of the following five criteria for MetS diagnosis: large waist circumference (women >88 and men >102 cm); elevated triglycerides (>150 mg/dl); low HDL cholesterol (men <40 and women <50 mg/dl); elevated blood pressure (>130/85 mmHg or self-reported use of medications for hypertension); and impaired fasting glucose (100–125 mg/dl) as defined in the updated American Heart Association/National Heart, Lung, and Blood Institute guidelines (1). Results also were analyzed using the International Diabetes Federation (IDF) definition of MetS.

Measurement of aortic valve calcium by CT.

AVC was measured using either electron-beam tomography (three sites) or multidetector CT (three sites). A total calcium score was determined by summing individual lesion scores at each anatomic site. Any calcified focus seen extending to the aortic root was deemed AVC by methodology described previously (2224). Calcification involving either the aortic or mitral annuli was not included. AVC score was assessed in every patient. The calcium score of each lesion was calculated by multiplying the lesion area by a density factor derived from the maximal Hounsfield units within this area as described by Agatston (25). The absence of AVC was deemed a score of 0. Details of the scanning methodology used for AVC in the MESA study have been reported (23), and the median interscan variability for Agatston AVC scores within the MESA cohort is 6.4% (23). All studies were analyzed at the MESA CT reading center at Harbor-UCLA.

To define AVC progression, a second AVC measurement was performed on a random selection of half the cohort at exam 2 (September 2002 to January 2004) and on the other half of the cohort at exam 3 (March 2004 to July 2005). The mean time between scans was 2.4 (±0.9) years.

Data analyses.

The study population for this analysis includes all MESA participants who had no missing data on any component of MetS with both baseline (exam 1) and follow-up (exam 2 or 3) CT scans. After applying these criteria, 5,723 individuals remained for analysis.

Participants were classified by the presence or absence of the MetS and diabetes, creating three groups (diabetes, MetS, and neither condition). Baseline demographics and laboratory measures were expressed with means and proportions and compared across groups using the χ2 test and ANOVA. Because the exact date of development of incident AVC is not known, risk time was calculated as the elapsed time from the baseline to the second or third MESA examination. Unadjusted incident AVC rates were calculated as the number of events divided by person-years at risk, and incident AVC rates were examined according to the three groups of neither condition, MetS, or diabetes.

Two end points were created and modeled separately. The primary outcome of interest was incident progression of AVC defined as detectable AVC (AVC score >0) at follow-up (either exam 2 or 3) among those with no AVC (AVC = 0) at the baseline examination. This was treated as a dichotomous end point, and yearly incidence rates were calculated among the three groups. Logistic regression was used to evaluate the association between incident AVC and the MetS and diabetes groups. Unadjusted analyses were performed followed by multivariable modeling that included age, ethnicity, and time between scans. A second adjusted model added LDL cholesterol, lipid-lowering medication use, smoking status, and scanner type (to account for scanner changes that were made at some of the sites).

A secondary outcome looked at AVC progression defined as an absolute change in AVC score among those with detectable AVC at exam 1. The absolute change was calculated as the difference between AVC score at follow-up and baseline. This was treated as a continuous end point for which we found that ~62 participants (10.3%) had very large residuals and therefore used robust linear regression to downweight their influence (26,27). The same modeling strategy used for incident AVC, as described, was used for AVC progression with additional adjustment for baseline AVC score.

We also looked at the number of MetS risk factors while treating diabetes as a separate category in order to explore relative associations of individual MetS components and of the number of components with incidence and progression of AVC using those with 0 MetS risk factors as the reference group. Because the numbers of participants who had four or five risk factors were relatively small, they were grouped together.

Interactions were evaluated between the three groups and each sex as well as between the three groups and each race. A P value ≤0.05 was considered statistically significant. Statistical analyses were performed with S-Plus (release 6.1; Insightful, Seattle, WA) and SPSS 15.0.1 software for Windows (SPSS, Chicago, IL).

RESULTS

Participant characteristics.

The study population for these analyses included 5,723 MESA subjects with a mean age of 62 years (SD = 10); 52% were female, 27% were African American, 12% were Chinese, and 22% were Hispanic. Of these, 1,674 (29%) met the ATP III definition for MetS and an additional 761 (13%) met the definition for diabetes. Table 1 shows the distribution of demographics and components of the MetS by MetS and diabetes groups. Participants with neither MetS nor diabetes were more likely to be younger; have lower values for BMI, triglycerides, and systolic blood pressure; and higher values for HDL. Large waist circumference was the most common component for the MetS (83%), whereas high blood pressure was the most common component for diabetes (77%).

TABLE 1
Characteristics of participants with diabetes, ATP III–defined MetS, or neither condition

Of the 5,123 participants with an AVC of 0 at baseline, 211 (4%) developed an AVC greater than 0 over follow-up (new “incident” AVC). The breakdown by condition is 88 (3%) for neither MetS nor diabetes, 79 (5%) for MetS, and 44 (7%) for diabetes (P < 0.0001). At baseline, there were 600 (11%) participants with AVC greater than 0 who were, therefore, classified as at risk for AVC progression. Of these, 266 (8%) had neither MetS nor diabetes, 204 (12%) had MetS only, and 130 (17%) had diabetes (P < 0.001). The median baseline AVC score for these 600 participants was 68 Agatston units (interquartile range [IQR] 25–152). The median (IQR) baseline AVC scores were, by condition, 54 (22–144) for neither MetS nor diabetes, 80 (25–178) for MetS, and 63 (27–113) for diabetes (P = 0.335).

Incident AVC

Rates for incident AVC by metabolic syndrome, diabetes, or neither condition.

Incident (“new”) AVC was higher among those with either MetS or diabetes as compared with those with neither condition. The yearly rate of incident AVC per 100 person-years (among participants without AVC at baseline) in subjects with the MetS was lower than in those with diabetes (Fig. 1, left). Rates of incident AVC were 2.2% per year in those with ATP III–defined MetS and 3.0% per year in those with diabetes as compared with 1.2% per year in those with neither (P = 0.0001 for ATP III MetS versus neither condition and P < 0.0001 for diabetes versus neither condition). Similar results were obtained using the IDF criteria for MetS (Fig. 1, right). There was no sex or race interaction for the relationship of either MetS or diabetes with incident AVC (P for interaction = 0.633 and 0.581, respectively).

FIG. 1.
Rates of incident AVC for diabetes (■), MetS ([striped box]), or neither condition (□) using MetS criteria as defined by ATP III (left) or IDF (right).

Rates of incident AVC by number of MetS components.

There was a graded, linear association between the rate of incident AVC and the number of MetS components. Those with diabetes had the highest rates of incident AVC (Fig. 2).

FIG. 2.
Rates of incident AVC by number of MetS components as defined by ATP III criteria (A) or IDF criteria (B). DM, diabetes.

Multivariable analyses: odds ratios for incident AVC.

In logistic regression analyses adjusted for age, sex, ethnicity, and time between scans, the odds ratios (ORs) for incident AVC were significantly higher in participants with either the MetS (1.73 [95% CI 1.25–2.38]) or diabetes (2.16 [1.46–3.19]) as compared with those with neither condition. These associations persisted after additional adjustment for LDL cholesterol, lipid-lowering medication use, and smoking (MetS, OR 1.67 [1.21–2.31], and diabetes, 2.06 [1.39–3.06]) (Table 2).

TABLE 2
Logistic regression models for the risk of incident AVC (among those free of AVC at baseline) and diabetes, MetS (by ATP III criteria), or neither condition

Risks for incident AVC by number of MetS components.

When examining the ORs for incident AVC by number of MetS components (Fig. 3), a similar pattern emerged. As compared with those with no MetS components, participants with three MetS risk factors, four to five MetS risk factors, and diabetes had a significantly increased risk of incident AVC in a model adjusted for age, sex, ethnicity, time between scans, LDL cholesterol, use of lipid-lowering medication, and smoking (OR, 1.88 [95% CI 1.01–3.51], 2.24 [1.16–4.30], and 2.50 [1.32–4.73], respectively).

FIG. 3.
Adjusted ORs (boxes) and corresponding 95% CIs (bars) for incident AVC by number of ATP III MetS criteria or diabetes (DM).

Incident AVC and individual MetS components.

We evaluated the association of individual components of the MetS with incident AVC (Table 3) in those participants without diabetes. Each of the five MetS components was added in the model simultaneously, and the model was then further adjusted for age, sex, ethnicity, time between scans, LDL cholesterol, lipid-lowering medication, and smoking. Incident AVC was only related to low HDL (adjusted OR 1.54 [95% CI 1.08–2.19]). In both unadjusted and demographic-adjusted analyses, there were associations between impaired fasting glucose and incident AVC, but these associations were attenuated and of marginal statistical significance after multivariable adjustment (1.36 [0.97–1.90]).

TABLE 3
Logistic regression models for the risk of incident AVC (among those free of AVC at baseline) for each component of the MetS in participants free of diabetes

Given the strong relationship of AVC among those with diabetes, we also looked at the association of continuous glucose (per 10 mg/dl). For participants without diabetes, the unadjusted model showed a strong increased risk between glucose and incident AVC (OR 1.33 [95% CI 1.14–1.55]). Although this risk was attenuated after full adjustment, it remained significantly elevated (1.18 [1.01–1.40]).

AVC progression.

Among those with AVC at baseline (n = 600), the median (IQR) annualized rate of AVC score change was 5.4 (−2.0 to 23.0) Agatston units per year. The rate of AVC score change did not vary significantly by MetS or diabetes status (P = 0.341 by Kruskal-Wallis) (Fig. 4). When examining the median AVC change by number of MetS components, no pattern emerged (P = 0.634 by Kruskal-Wallis, results not shown). Adjusted robust regression also showed that there was no significant AVC progression in Agatston units per year for either the MetS or diabetes compared with neither condition (results not shown).

FIG. 4.
Median AVC change by diabetes, MetS, or neither condition. “Box” plots the median AVC progression score (middle horizontal lines) in Agatston units/year and corresponding 25th (lower bound of box) and 75th (upper bound of box) percentile ...

DISCUSSION

Only one prospective study has demonstrated an association of MetS with increased risk for prevalent AVC (16), whereas retrospective studies have demonstrated that MetS is associated with increased rates of aortic stenosis progression (17) and bioprosthetic valve deterioration (18). AVC incidence is more important than prevalent AVC because it provides stronger evidence in establishing causality. By separating predictor and outcome variable over time, the longitudinal analysis reduces systematic bias and enhances causal inference. The present study is the first to prospectively examine the relationship of MetS to risks for incident (“new”) AVC and AVC progression. In fully adjusted analyses, both MetS and the number of MetS components were associated strongly with increased risk for incident AVC. We did not, however, identify an association of either MetS or diabetes with the rate of AVC progression.

The relationship of advanced dysglycemia, that is, clinical diabetes, to aortic valve disease pathology has been demonstrated in previous small, retrospective studies reporting associations of diabetes with increased prevalence of AVC (28) as well as with increased prevalence (29) and progression (30) of aortic stenosis. We and others have extended the relationship of less severe dysglycemia, that is, MetS, to aortic valve disease pathology by demonstrating that MetS is associated not only with increased prevalence of AVC (16), but also with faster aortic stenosis progression (17) and more rapid deterioration of bioprosthetic aortic valves (18). The results of the present study further extend the relationship of MetS to early-stage aortic valve disease pathology by demonstrating that MetS and MetS components are associated with an increased rate of new (“incident”) AVC. In our study, participants with diabetes and the MetS had the highest prevalence of new (“incident”) AVC.

The association of the dysglycemias, including diabetes and MetS, with increased risks for prevalent vascular (6,7) and valvular (16) calcification has been established, and interesting studies have begun to elucidate potential mechanisms that may underlie these associations. The key osteogenic regulatory factor, bone morphogenic protein (BMP)2, is upregulated by hyperglycemia in vitro. (31,32) BMP2 has been demonstrated to play a role in vascular calcification (33,34) and has been detected in areas of valvular calcification (35). BMP2 upregulates both “osteogenic” differentiation regulated by the transcription factor Msx2 and “chondro-ostegenic” differentiation regulated by the transcription factor Runx2/Cbfa1 (36).

Diabetes is characterized by a pro-oxidant state (37,38). Not only are oxidized lipoproteins present in human aortic valve lesions (39), but oxidized lipids also have been shown to upregulate the rate of calcium nodule formation in valvular cells in vitro (40). Several potential mechanisms may contribute to the increased risk of incident AVC seen with metabolic syndrome and diabetes.

These observational findings also are interesting in light of the recent demonstration that an elevated total-to-HDL cholesterol ratio is associated with a consistent increase in relative risk for AVC across all ages in the MESA cohort (41). Clinical abnormalities of glucose metabolism (which include impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes) are associated with both a progressive increase triglyceride-rich VLDL cholesterol and a progressive decrease in HDL cholesterol (8). Together, these changes increase the total-to-HDL cholesterol ratio (42). Retrospective studies had suggested a potential benefit of statin therapy (which primarily lowers LDL levels) in aortic valve disease (4346). The results of subsequent, properly controlled clinical trials of atorvastatin (47) or of simvastatin plus ezetimibe (48) have been convincingly negative despite average therapy-related LDL reductions of over 50% in both trials. Because the characteristic MetS lipid abnormalities of high triglycerides and low HDL result in an increase in the total-to-HDL cholesterol ratio, it is not known whether more specifically targeting this MetS-associated dyslipidemia might represent an effective strategy for decreasing the MetS-associated risks for incident AVC.

Recent studies have implicated the renin-angiotensin system, which is upregulated in MetS (2) in aortic valve disease pathogenesis (4952). Retrospective studies of ACE inhibitor therapy have been mixed in the general population of individuals with aortic sclerosis (50) or aortic stenosis (46). The results of the present study, however, raise the possibility that renin-angiotensin system inhibitor therapy targeted to those with MetS might prove effective at slowing the rate of development of CAVD.

The association of progressive increase in plasma glucose with progressive increase in risk for incident AVC risk raises the possibility that dysglycemia may represent an additional therapeutic target in this disease, as has been demonstrated for atherosclerosis (53).

This study has limitations, which include the possibility of survival bias, because those with clinical cardiovascular disease were excluded from MESA; limited statistical power, because the exclusion of those with known cardiovascular disease from MESA may have also resulted in the exclusion of individuals with MetS (1,2) and AVC (16), thereby limiting our power to show a relationship between MetS and AVC progression; dichotomization of continuous measures such as MetS components, which may decrease available information and result in misclassification of exposure; and survival bias attributed to participants who did not attend the follow-up examinations; and given the relatively short follow-up time, it is possible that AVC may not have developed between visits or AVC may not have been captured by CT scans. Nonetheless, MetS is defined using cut points in clinical practice. It is reassuring that similar results were found using both ATP III and IDF MetS criteria. Strengths of this study include use of a large, well-characterized, population-based cohort and of a highly reproducible technique for quantifying AVC.

This study formally tests the hypothesis that MetS is associated with increased risk for the development of AVC. These findings further underscore the clinical importance of identifying MetS in populations without clinical cardiovascular disease and, further, raise the possibility of screening for the presence of aortic valve disease in those with MetS. These findings suggest that future studies targeting the MetS-associated “atherogenic dyslipidemia” of high triglycerides and low HDL cholesterol as well as renin-angiotensin system components and/or insulin resistance may identify useful strategies to decrease the development of aortic valve disease.

Acknowledgments

This research was supported by R01-HL071739 and by contracts N01-HC-95159 through N01-HC-95165 and N01-HC-95169 from the National Heart, Lung, and Blood Institute (NHLBI). The NHLBI participated in the design and conduct of the MESA study.

M.J.B. has received honoraria from and is on the speakers' bureau of General Electric. K.D.O. has received honoraria from and is on the speakers' bureaus of AstraZeneca, Bristol-Myers Squibb, and Merck. No other potential conflicts of interest relevant to this article were reported.

Parts of this study were presented in abstract form during the American Heart Association Scientific Sessions, New Orleans, Louisiana, 8–12 November 2008.

We thank Susan Larsen for assistance in manuscript preparation and the other investigators, staff, and participants of the MESA study for their valuable contributions.

Notes

*A full list of participating MESA investigators and institutions may be found at http://www.mesa-nhlbi.org.

Footnotes

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

REFERENCES

1. Grundy SM, Cleeman I, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Jr, Spertus JA, Costa F.: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735– 2752, 2005. [PubMed]
2. Eckel RH, Grundy SM, Zimmet PZ.: The metabolic syndrome. Lancet 365: 1415– 1428, 2005. [PubMed]
3. Ford ES, Giles WH, Dietz WH.: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287: 356– 359, 2002. [PubMed]
4. Zimmet P, Alberti KG, Shaw J.: Global and societal implications of the diabetes epidemic. Nature 414: 782– 787, 2001. [PubMed]
5. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP.: The continuing epidemics of obesity and diabetes in the United States. JAMA 286: 1195– 1200, 2001. [PubMed]
6. Arad Y, Newstein D, Cadet F, Roth M, Guerci AD.: Association of multiple risk factors and insulin resistance with increased prevalence of asymptomatic coronary artery disease by an electron-beam computed tomographic study. Arterioscler Thromb Vasc Biol 21: 2051– 2058, 2001. [PubMed]
7. Wong ND, Sciammarella MG, Polk D, Gallagher A, Miranda-Peats L, Whitcomb B, Hachamovitch R, Friedman JD, Hayes S, Berman DS.: The metabolic syndrome, diabetes, and subclinical atherosclerosis assessed by coronary calcium. J Am Coll Cardiol 41: 1547– 1553, 2003. [PubMed]
8. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24: 683– 689, 2001. [PubMed]
9. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288: 2709– 2716, 2002. [PubMed]
10. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J., III: Factors of risk in the development of coronary heart disease—six year follow-up experience. The Framingham Study. Ann Intern Med 55: 33– 50, 1961. [PubMed]
11. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM.: Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 29: 630– 634, 1997. [PubMed]
12. Otto CM, Pearlman AS.: Doppler echocardiography in adults with symptomatic aortic stenosis. Diagnostic utility and cost-effectiveness. Arch Intern Med 148: 2553– 2560, 1988. [PubMed]
13. Carabello BA.: Clinical practice. Aortic stenosis. N Engl J Med 346: 677– 682, 2002. [PubMed]
14. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS.: Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 341: 142– 147, 1999. [PubMed]
15. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, Kraft CD, Miyake-Hull CY, Schwaegler RG.: Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 95: 2262– 2270, 1997. [PubMed]
16. Katz R, Wong ND, Kronmal R, Takasu J, Shavelle DM, Probstfield JL, Bertoni AG, Budoff MJ, O'Brien KD.: Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 113: 2113– 2119, 2006. [PubMed]
17. Briand M, Lemieux I, Dumesnil JG, Mathieu P, Cartier A, Despres JP, Arsenault M, Couet J, Pibarot P.: Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol 47: 2229– 2236, 2006. [PubMed]
18. Briand M, Pibarot P, Despres JP, Voisine P, Dumesnil JG, Dagenais F, Mathieu P.: Metabolic syndrome is associated with faster degeneration of bioprosthetic valves. Circulation 114: I512– I517, 2006. [PubMed]
19. Bild DE, Bluemke DA, Burke GL, Detrano R, ez Roux AV, Folsom AR, Greenland P, Jacob DR, Jr, Kronmal R, Liu K, Nelson C, O'Leary D, Saad MF, Shea S, Szklo M, Tracy RP.: Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol 156: 871– 881, 2002. [PubMed]
20. Friedewald WT, Levy RI, Fredrickson DS.: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499– 502, 1972. [PubMed]
21. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486– 2497, 2001. [PubMed]
22. Budoff MJ, Mao S, Takasu J, Shavelle DM, Zhao XQ, O'Brien KD.: Reproducibility of electron-beam CT measures of aortic valve calcification. Acad Radiol 9: 1122– 1127, 2002. [PubMed]
23. Budoff MJ, Takasu J, Katz R, Mao S, Shavelle DM, O'Brien KD, Blumenthal RS, Carr J, Kronmal R.: Reproducibility of CT measurements of aortic valve calcification, mitral annulus calcification, and aortic wall calcification in the Multi-Ethnic Study of Atherosclerosis. Acad Radiol 13: 166– 172, 2006. [PubMed]
24. Budoff MJ, Katz R, Wong ND, Nasir K, Mao SS, Takasu J, Kronmal R, Detrano RC, Shavelle DM, Blumenthal RS, O'Brien KD, Carr JJ.: Effect of scanner type on the reproducibility of extracoronary measures of calcification: the Multi-Ethnic Study of Atherosclerosis. Acad Radiol 14: 1043– 1049, 2007. [PubMed]
25. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Jr, Detrano R.: Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15: 827– 832, 1990. [PubMed]
26. Martin RD.: Robust Statistics With the S-Plus Robust Library and Financial Applications New York: Insightful; 2002
27. Venables WN, Ripley BD.: Modern Applied Statistics With S-Plus New York: Springer; 1999: 167– 176
28. Boon A, Cheriex E, Lodder J, Kessels F.: Cardiac valve calcification: characteristics of patients with calcification of the mitral annulus or aortic valve. Heart 78: 472– 474, 1997. [PMC free article] [PubMed]
29. Aronow WS, Schwartz KS, Koenigsberg M.: Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am J Cardiol 59: 998– 999, 1987. [PubMed]
30. Aronow WS, Ahn C, Kronzon I, Goldman ME.: Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 88: 693– 695, 2001. [PubMed]
31. Zhang L, Zalewski A, Liu Y, Mazurek T, Cowan S, Martin JL, Hofmann SM, Vlassara H, Shi Y.: Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation 108: 472– 478, 2003. [PubMed]
32. Cheng SL, Shao JS, Charlton-Kachigian N, Loewy AP, Towler DA.: MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J Biol Chem 278: 45969– 45977, 2003. [PubMed]
33. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL.: Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 91: 1800– 1809, 1993. [PMC free article] [PubMed]
34. Watson KE, Bostrom K, Ravindranath R, Lam T, Norton B, Demer LL.: TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest 93: 2106– 2113, 1994. [PMC free article] [PubMed]
35. Mohler ER, III, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS.: Bone formation and inflammation in cardiac valves. Circulation 103: 1522– 1528, 2001. [PubMed]
36. Wozney JM, Rosen V.: Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop Relat Res 346: 26– 37, 1998. [PubMed]
37. Baynes JW, Thorpe SR.: Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 28: 1708– 1716, 2000. [PubMed]
38. Pennathur S, Wagner JD, Leeuwenburgh C, Litwak KN, Heinecke JW.: A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest 107: 853– 860, 2001. [PMC free article] [PubMed]
39. Olsson M, Thyberg J, Nilsson J.: Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 19: 1218– 1222, 1999. [PubMed]
40. Mohler ER, III, Chawla MK, Chang AW, Vyavahare N, Levy RJ, Graham L, Gannon FH.: Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis 8: 254– 260, 1999. [PubMed]
41. Owens DS, Katz R, Johnson E, Shavelle DM, Probstfield JL, Takasu J, Crouse JR, Carr JJ, Kronmal R, Budoff MJ, O'Brien KD.: Interaction of age with lipoproteins as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Arch Intern Med 168: 1200– 1207, 2008. [PubMed]
42. Tannock LR, O'Brien KD, Knopp RH, Retzlaff B, Fish B, Wener MH, Kahn SE, Chait A.: Cholesterol feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive subjects. Circulation 111: 3058– 3062, 2005. [PubMed]
43. Novaro GM, Tiong Y, Pearce GL, Lauer MS, Sprecher DL, Griffin BP.: Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 104: 2205– 2209, 2001. [PubMed]
44. Pohle K, Maffert R, Ropers D, Moshage W, Stilianakis N, Daniel WG, Achenbach S.: Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 104: 1927– 1932, 2001. [PubMed]
45. Shavelle DM, Takasu J, Budoff MJ, Mao S, O'Brien KD.: HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 359: 1125– 1126, 2002. [PubMed]
46. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M, Binder T, Maurer G, Baumgartner H.: Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110: 1291– 1295, 2004. [PubMed]
47. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA.: A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352: 2389– 2397, 2005. [PubMed]
48. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Barwolf C, Holme I, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R.: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359: 1343– 1356, 2008. [PubMed]
49. O'Brien KD, Shavelle DM, Caulfield MT, McDonald TO, Olin-Lewis K, Otto CM, Probstfield JL.: Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 106: 2224– 2230, 2002. [PubMed]
50. O'Brien KD, Probstfield JL, Caulfield MT, Nasir K, Takasu J, Shavelle DM, Wu AH, Zhao XQ, Budoff MJ.: Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 165: 858– 862, 2005. [PubMed]
51. Helske S, Lindstedt KA, Laine M, Mayranpaa M, Werkkala K, Lommi J, Turto H, Kupari M, Kovanen PT.: Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 44: 1859– 1866, 2004. [PubMed]
52. Arishiro K, Hoshiga M, Negoro N, Jin D, Takai S, Miyazaki M, Ishihara T, Hanafusa T.: Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol 49: 1482– 1489, 2007. [PubMed]
53. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA.: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577– 1589, 2008. [PubMed]

Articles from Diabetes are provided here courtesy of American Diabetes Association